Patient and Provider Perspectives on Acceptability, Access, and Adherence to 17-Alpha-Hydroxyprogesterone Caproate for Preterm Birth Prevention-Reference-Cited by-同舟云学术

Patient and Provider Perspectives on Acceptability, Access, and Adherence to 17-Alpha-Hydroxyprogesterone Caproate for Preterm Birth Prevention

Published:2021-07-01 Issue:1 Volume:2 Page:295-304
ISSN:2688-4844
Container-title:Women's Health Reports
language:en
Short-container-title:Women's Health Reports

Author:

Garcia Stephanie M.¹^ORCID,Kellom Katherine S.¹,Boelig Rupsa C.²,Wang Xi¹,Matone Meredith³

Affiliation:

1. PolicyLab, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.

2. Division of Maternal Fetal Medicine and Department of Pharmacology and Experimental Therapeutics, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.

3. PolicyLab, Children's Hospital of Philadelphia and Department of Pediatrics, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.

Publisher

Mary Ann Liebert Inc

Link

https://www.liebertpub.com/doi/pdf/10.1089/whr.2021.0022

Reference38 articles.

1. Practice Bulletin No. 130

2. The choice of progestogen for the prevention of preterm birth in women with singleton pregnancy and prior preterm birth

3. Prevention of Recurrent Preterm Delivery by 17 Alpha-Hydroxyprogesterone Caproate

4. Understanding barriers to uptake of 17 alpha-hydroxyprogesterone caproate (17-OHP) in women with history of preterm birth

5. Improving Uptake and Adherence to 17-Hydroxyprogesterone Caproate in Non-Hispanic Black Women: A Mixed Methods Study of Potential Interventions from the Patient Perspective

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Vaginal progesterone vs intramuscular 17-hydroxyprogesterone caproate for prevention of recurrent preterm birth: a randomized controlled trial;American Journal of Obstetrics and Gynecology;2022-05